Literature DB >> 27817743

New Insights into the Roles of NAD+-Poly(ADP-ribose) Metabolism and Poly(ADP-ribose) Glycohydrolase.

Seiichi Tanuma1, Akira Sato, Takahiro Oyama, Atsushi Yoshimori, Hideaki Abe, Fumiaki Uchiumi.   

Abstract

Accumulating evidence has suggested the fundamental functions of NAD+-poly(ADP-ribose) metabolism in cellular and physiological processes, including energy homeostasis, signal transduction, DNA transaction, genomic stability and cell death or survival. The NAD+ biosynthesis and poly(ADP-ribose) [(ADP-R)n] turnover are tightly controlled by several key enzymes, such as nicotinamide phosphoribosyltransferase (NmPRT), nicotinamide mononucleotide adenylyltransferases (NMNATs), poly(ADP-ribose) polymerase (PARP), poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribose pyrophosphorylase (ADPRPPL). Many researches investigating the roles of these enzymes in cells have revealed the physiological and pathological importance, and thereby the therapeutical values. Among these enzymes, the polymer degrading enzyme PARG has not yet been intensively studied, because of the low cellular content, lack of cell-available PARG chemical inhibitors and PARG genetic models. So, the biological roles of (ADP-R)n catabolism by PARG are still being elucidated as compared to those of synthesis by PARP. However, recent studies delineate that PARG-dependent (ADP-R)n degradation is critical for many pathological conditions, and thus PARG is an important target for chemical therapeutics for several diseases. This review will present the recent progresses about the roles of NAD+-(ADP-R)n metabolism and the structures and functions of PARG, with a focus on its role in DNA repair and cell death by apoptosis in relation to central regulatory network, and the therapeutic potentials of PARG inhibitors in cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27817743     DOI: 10.2174/1389203717666160419150014

Source DB:  PubMed          Journal:  Curr Protein Pept Sci        ISSN: 1389-2037            Impact factor:   3.272


  12 in total

Review 1.  Emerging roles of ADP-ribosyl-acceptor hydrolases (ARHs) in tumorigenesis and cell death pathways.

Authors:  Xiangning Bu; Jiro Kato; Joel Moss
Journal:  Biochem Pharmacol       Date:  2018-09-27       Impact factor: 5.858

2.  A transcriptomics approach uncovers novel roles for poly(ADP-ribosyl)ation in the basal defense response in Arabidopsis thaliana.

Authors:  Amy G Briggs; Lori C Adams-Phillips; Brian D Keppler; Sophia G Zebell; Kyle C Arend; April A Apfelbaum; Joshua A Smith; Andrew F Bent
Journal:  PLoS One       Date:  2017-12-28       Impact factor: 3.240

3.  Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment.

Authors:  Yoko Ogino; Akira Sato; Fumiaki Uchiumi; Sei-Ichi Tanuma
Journal:  Oncotarget       Date:  2018-03-27

4.  CD38 promotes pristane-induced chronic inflammation and increases susceptibility to experimental lupus by an apoptosis-driven and TRPM2-dependent mechanism.

Authors:  Sonia García-Rodríguez; Antonio Rosal-Vela; Davide Botta; Luz M Cumba Garcia; Esther Zumaquero; Verónica Prados-Maniviesa; Daniela Cerezo-Wallis; Nicola Lo Buono; José-Ángel Robles-Guirado; Salvador Guerrero; Elena González-Paredes; Eduardo Andrés-León; Ángel Corbí; Matthias Mack; Friedrich Koch-Nolte; Ramón Merino; Mercedes Zubiaur; Frances E Lund; Jaime Sancho
Journal:  Sci Rep       Date:  2018-02-20       Impact factor: 4.379

5.  Understanding D-Ribose and Mitochondrial Function.

Authors:  Diane E Mahoney; John B Hiebert; Amanda Thimmesch; John T Pierce; James L Vacek; Richard L Clancy; Andrew J Sauer; Janet D Pierce
Journal:  Adv Biosci Clin Med       Date:  2018

6.  ADP-ribosylation signalling and human disease.

Authors:  Luca Palazzo; Petra Mikolčević; Andreja Mikoč; Ivan Ahel
Journal:  Open Biol       Date:  2019-04-26       Impact factor: 6.411

7.  Restriction of AID activity and somatic hypermutation by PARP-1.

Authors:  Sandra Tepper; Oliver Mortusewicz; Ewelina Członka; Amanda Bello; Angelika Schmidt; Julia Jeschke; Arthur Fischbach; Ines Pfeil; Svend K Petersen-Mahrt; Aswin Mangerich; Thomas Helleday; Heinrich Leonhardt; Berit Jungnickel
Journal:  Nucleic Acids Res       Date:  2019-08-22       Impact factor: 16.971

Review 8.  (ADP-ribosyl)hydrolases: structure, function, and biology.

Authors:  Johannes Gregor Matthias Rack; Luca Palazzo; Ivan Ahel
Journal:  Genes Dev       Date:  2020-02-06       Impact factor: 11.361

9.  Silibinin Restores NAD⁺ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver.

Authors:  Federico Salomone; Ignazio Barbagallo; Justyna Godos; Vincenzo Lembo; Walter Currenti; Diana Cinà; Roberto Avola; Nicolantonio D'Orazio; Filomena Morisco; Fabio Galvano; Giovanni Li Volti
Journal:  Nutrients       Date:  2017-09-30       Impact factor: 5.717

Review 10.  Asthma and poly(ADP-ribose) polymerase inhibition: a new therapeutic approach.

Authors:  Raffaela Zaffini; Giovanni Gotte; Marta Menegazzi
Journal:  Drug Des Devel Ther       Date:  2018-02-12       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.